Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

1.390 +0.030 (+2.21%)
Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 639,398
Open 1.380
Bid (Size) 1.300 (2)
Ask (Size) 1.580 (2)
Prev. Close 1.360
Today's Range 1.380 - 1.425
52wk Range 1.240 - 4.600
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for Amneal Pharmaceuticals
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga

Performance

YTD
-34.12%
-34.12%
1 Month
-30.15%
-30.15%
3 Month
-34.12%
-34.12%
6 Month
-33.17%
-33.17%
1 Year
-67.67%
-67.67%

More News

Read More
Amneal Seeks FDA Approval For Its Parkinson's Candidate
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Via Investor's Business Daily
Amneal Announces Strategic European Partnership with Orion Corporation
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Amneal Reports Third Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 4, 2022
Via Benzinga
Earnings Outlook For Amneal Pharmaceuticals
Via Benzinga
Amneal Receives FDA Approval for Leuprolide Acetate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Third Quarter 2022 Results on November 4, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.